BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22592665)

  • 41. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension.
    Littlejohn TW; Trenkwalder P; Hollanders G; Zhao Y; Liao W
    Curr Med Res Opin; 2009 Apr; 25(4):951-9. PubMed ID: 19257800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥.
    Pfeiffer D; Rennie N; Papst CC; Zhang J
    Curr Vasc Pharmacol; 2012 Nov; 10(6):773-80. PubMed ID: 22303911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
    Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.
    Drummond W; Munger MA; Rafique Essop M; Maboudian M; Khan M; Keefe DL
    J Clin Hypertens (Greenwich); 2007 Oct; 9(10):742-50. PubMed ID: 17917501
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.
    Szeto CC; Kwan BC; Chow KM; Leung CB; Li PK
    PLoS One; 2013; 8(5):e62736. PubMed ID: 23675422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide.
    Ando K; Isshiki M; Takahashi K;
    Hypertens Res; 2009 Sep; 32(9):748-52. PubMed ID: 19590506
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
    Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y
    Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.
    Angeli F; Reboldi G; Mazzotta G; Poltronieri C; Garofoli M; Ramundo E; Biadetti A; Verdecchia P
    Curr Drug Saf; 2012 Feb; 7(1):76-85. PubMed ID: 22663961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
    J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.
    Brown MJ; McInnes GT; Papst CC; Zhang J; MacDonald TM
    Lancet; 2011 Jan; 377(9762):312-20. PubMed ID: 21236483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial.
    Wu MT; Tung SC; Hsu KT; Lee CT
    J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):271-7. PubMed ID: 23223162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
    Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
    J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
    Musini VM; Lawrence KA; Fortin PM; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007066. PubMed ID: 28379619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Sugaya T; Yamagishi S; Yamada S; Koide H
    Am J Med Sci; 2010 Feb; 339(2):157-63. PubMed ID: 20145433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.
    Lanier G; Sankholkar K; Aronow WS
    Am J Ther; 2014; 21(5):419-35. PubMed ID: 22975662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R; Frishman WH; Stier CT; Sica DA
    Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.